Testagen

Testagen is commonly mapped to the KEDG tetrapeptide, described in some papers as a hypophyseal anterior-pituitary peptide. Defensible sources support only narrow endocrine and immune-model discussion, not broad male reproductive claims. PubMed-indexed animal studies in hypophysectomized birds reported that Lys-Glu-Asp-Gly affected thyroid morphology and hormone activity, including TSH, T3, and T4 changes. Related work reported changes in thymus morphology, immunity, hemostasis, and thyroid function in avian models. These data are preclinical and not equivalent to testosterone, fertility, or testicular-function outcomes in humans.

Pituitary-Thyroid Animal Models

KEDG was studied in hypophysectomized mature and old birds, with reported effects on thyroid morphology and TSH, T3, and T4 activity ^[1].

Thymus and Immune Models

KEDG and AEDG promoted recovery of thymic structures and were studied for immunity, hemostasis, and thyroid function in hypophysectomized birds ^[2][3].

Evidence Boundary

Direct human testosterone, fertility, or testicular-function benefits were not supported by the cleared primary sources ^[1][2][3].

Human Data Gap

No controlled human safety or efficacy studies for Testagen/KEDG were located ^[1][2][3].

Endocrine Translation Risk

Animal endocrine effects involving TSH, T3, and T4 create theoretical thyroid-axis risk if translated outside research settings. Human dose-response and monitoring parameters are unknown ^[1].